Barely Significant
← all phrases

“showed a trend”

53,323 sentences · 53,323 papers · 65,371 search hits before verification

In the literature

183 TWIST1 silencing in an in vivo xenograft model showed decreased metastatic burden, and regardless of metastasis status in patients, positive expression of TWIST1 showed a trend toward lower survival. 183 Another recent discovery was the oncogenic potential of KDM3A , a histone demethylase, in ES. 184 KDM3A silencing in vitro showed a 50% decrease in migration and invasion and a tenfold decrease in metastatic burden compared to controls (in mice). 184 MCAM , which is also involved in metastasis in other cancers, is a direct downstream target of KDM3A , and when silenced, recapitulated impaired proliferation and metastasis are observed with KDM3A silencing.
Visual evoked potential-VEP and median nerve SEP (N13-N20) also showed a trend of stabilization or amelioration of latencies over time in treatment groups, although these differences didn ́t reach statistically significance over the time, as well as between groups;(p.F = 0,59; p.kW = 0,89).
In in vivo studies, the changes of Asp levels in the five brain regions of rats during the process of anaesthesia showed a trend of a decrease followed by an increase, suggesting that xylazine may inhibit Asp synthesis and release, reducing excitatory neurotransmitter and receptor binding, ultimately reducing the excitability of neurons and producing anaesthetic effects.
The results showed a trend for reduction in the incidence of primary CV outcomes in metformin-treated patients contrasting with a trend for an increase in MACE in patients not receiving metformin. 73 As the between-group was statistically significant, it was considered that metformin may act as a CV moderator of DPP-4 inhibitors, but obviously these hypothesis-generating findings require further confirmation. 74 Indeed, possible bias could not be excluded, especially because a major reason for not prescribing metformin may have been CKD, a condition known to be associated with higher CV risk as already mentioned.
In CMM, there was also significantly greater pS6+/S6+ cell density in the Trained-Novel group compared to the Trained-Familiar group (CMM: P = 2.26E −5 ; NCM: P = 0.42); NCM showed a trend for Trained-Familiar mTOR activation levels to be intermediate between those of both the Trained-Silence and Trained-Novel conditions (mean ± SEM: Trained-Silence: 0.061 ± 0.01; Trained-Familiar: 0.18 ± 0.024; Trained-Novel: 0.24 ± 0.035).
However, patients treated with Ada showed a trend towards more activated T cells (median 26.5%, IQR 14.4–33.6% for CD4 + and median 12.5%, IQR 6.9–18.3% for CD8 + ) as compared to those treated with Eta (median 14.6%, IQR 7–27.2% for CD4 + and median 4.8%, IQR 2.5–13.9% for CD8 + ) (p = 0.16 for CD4 + and p = 0.25 for CD8 + ; Fig. 2c ).
MitoQ and Nac, when administered alone, showed a trend similar to the untreated condition in both timings (12 h: MitoQ: 117 ± 19.81; Nac: 99.33 ± 5.16; Untr: 100.1 ± 10.47; ns) (48 h: MitoQ: 105.1 ± 13.48; Nac: 93.67 ± 12.53; Untr: 100 ± 10.01; ns) ( Figure 2 B,C).